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Objectives: The aim of this study was to review and compare current health technology assessment (HTA) activities for medical devices across non-European Union HTA agencies.
Methods: HTA activities for medical devices were evaluated from three perspectives: organizational structure, processes, and methods. Agencies were primarily selected upon
membership of existing HTA networks. The data collection was performed in two stages: stage 1–agency Web-site assessment using a standardized questionnaire, followed by
review and validation of the collected data by a representative of the agency; and stage 2–semi-structured telephone interviews with key informants of a sub-sample of agencies.
Results: In total, thirty-six HTA agencies across twenty non-EU countries assessing medical devices were included. Twenty-seven of thirty-six (75 percent) agencies were judged at
stage 1 to have adopted HTA-specific approaches for medical devices (MD-specific agencies) that were largely organizational or procedural. There appeared to be few differences in
the organization, process and methods between MD-specific and non–MD-specific agencies. Although the majority (69 percent) of both categories of agency had specific methods
guidance or policy for evidence submission, only one MD-specific agency had developed methodological guidelines specific to medical devices. In stage 2, many MD-specific agencies
cited insufficient resources (budget, skilled employees), lack of coordination (between regulator and reimbursement bodies), and the inability to generalize findings from evidence
synthesis to be key challenges in the HTA of medical devices.
Conclusions: The lack of evidence for differentiation in scientific methods for HTA of devices raises the question of whether HTA needs to develop new methods for medical devices
but rather adapt existing methodological approaches. In contrast, organizational and/or procedural adaptation of existing HTA agency frameworks to accommodate medical devices
appear relatively commonplace.
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Health technology assessment (HTA) seeks to provide policy
makers with information on the clinical and economic value
of health technologies (including pharmaceuticals, medical de-
vices (MDs), clinical procedures, and organizational systems
used in health care) to inform their reimbursement or coverage
decisions (1).
Several surveys have been undertaken to date that describe
and compare the HTA activities across organizations and coun-
tries (2–6). For example, in 2008, the European Network for
Health Technology Assessment (EUnetHTA) published an in-
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ternational survey of HTA organizations examining the barriers
and solutions for establishment of the HTA units, their charac-
teristics and processes (6). These previous surveys have tended
to focus on drugs rather than non-drug technologies (7), often
because “the use of HTA information in the reimbursement of
pharmaceuticals is currently the most advanced area of research
in the discipline” (3). However, the report byWilsdon and Serota
showed that several countries have HTA systems in place with
a mandate to include non-drug technologies, including MDs
(8). This report also confirmed that the number of HTA reports
devoted to non-drug technologies remain in the minority.
The evaluation of non-drug technologies, in particularMDs,
may pose different challenges to those of pharmaceuticals.
Compared with drugs, undertaking randomized controlled tri-
als are often more difficult, product modification occurs more
frequently, pricing is more dynamic, and clinical outcomes
are more depending on training, competence, and experience
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(“learning curve”) of the operator (9;10). It is often difficult to
disentangle procurement costs (including associated infrastruc-
ture) and running costs (including maintenance and consum-
ables) of MDs (11).
The aim of this study was to undertake a survey of non-
European Union (EU) HTA agencies to characterize and con-
trast their activities for MDs in terms of: (i) organizational
structure; (ii) processes, that is, standard operating procedures
in use; and (iii) methods, that is, scientific methodologies and
assessment in place. This study was undertaken as part of
the MedTecHTA project (www.medtechta.eu), funded under
the EU’s 7th Framework Program (FP7). Under the condi-
tions of this EU-FP7 funding, the MedTecHTA project was
directed to undertake a survey of MD activities in non-EU
HTA agencies. The EU-FP7 funded ADVANCE-HTA project
(www.advance-hta.eu) project is responsible for a parallel sur-
vey of MD activity in EU HTA agencies.
METHODS
Selection of HTA agencies
We considered institutionalized HTA activities (12) and se-
lected HTA organizations based on their membership, as of
February 2013, of European network for HTA (EUnetHTA),
Health Technology Assessment International (HTAi), Interna-
tional Network of Agencies for Health Technology Assessment
(INAHTA) or World Health Organization (WHO) Collaborat-
ing Centres for HTA. In addition, we performed a search to
identify additional HTA agencies who were not potential mem-
bers of these networks. To be included, organizations had to
be an HTA agency based on the HTA definition proposed by
Kristensen (13). Based on this definition, patient and industry
organizations were excluded.
Development of an Evaluative Framework
Our assessment of HTA for MDs was based on the key princi-
ples for the improved conduct of HTA proposed by Drummond
et al. (14). HTA activities were evaluated from three perspec-
tives: Organizational structure: what are the HTA roles of the
organization and how is it organized and governed? (e.g., sep-
arate department or allocation of resources or deployment of
people to the HTA of MDs versus drugs); Processes: how does
the organization conduct HTA and involve stakeholders? (e.g.,
separate decision-making committee, degree of stakeholder in-
teraction or amount of time it time of completion of HTA versus
drugs); andMethods: what methodologies are used for an HTA?
(i.e., specific scientificmethod guidelines for assessing evidence
related to MDs versus drugs).
We undertook a two-stage data collection process. In stage
1, we performed: (i) a review of the literature to understand
the HTA system in each country, (ii) a review of agency Web
sites using a standardized questionnaire, and (iii) review and
validation of the completed Web site questionnaires by a senior
representative of the agency. In stage 2,we conducted semistruc-
tured telephone interviews with key informants of the agencies
that were identified at stage 1 as having developed specific HTA
activities for MDs (see Supplementary Figure 1).
Stage 1: Literature Review, Web Site Data Collection, and Verification of Results. First,
we reviewed published literature describing the HTA system in
each of the included countries to understand the interactions
and players involved from a macro perspective. This involved a
Medline (PubMed) search (“country” AND (“Health Technol-
ogy Assessment” OR “HTA”)). From this information, we de-
veloped a “map” summarizing the links between HTA agencies
and other key stakeholders (e.g., regulatory agencies) (15;16).
A questionnaire based upon a literature review of HTA of
MDs and previous HTA survey (8;17;18) was developed to
collate information available of the agencies’ Web sites. The
questionnaire consisted of fifty items (forty-four closed and six
open questions) from four sections (i.e., Section A - agency
information, Section B - structure of HTA agency, Section C -
agency HTA processes, and Section D - agency HTA methods.
A copy of this Web-site assessment questionnaire is available
from authors). Data extraction was performed by one researcher
and checked by a second.
For verification of the collected data, a key strategic individ-
ual within each agency (e.g., Chief Operating Executive, Head
of HTA Agency) was e-mailed a copy of our completed Web
site questionnaire assessment and the country level HTA map.
After verification, if applicable, these individuals were asked if
they would participate in a follow up semistructured interview.
Stage 2: Semistructured Interviews of SelectedHTAAgencies. Interviewswere con-
ducted in the subgroup of HTA agencies identified from Stage
1 to have MD-specific processes in terms of their structure,
processes, or methods. The objective of the interviews were:
(i) to clarify items reported in the Web based data collection
process and (ii) to determine how the organizational framework
mitigates challenges associated with performing HTA on MDs.
If individuals did not respond to the initial invitation e-mail
letter and the reminders, other key informants of the agency
were identified and asked if they would participate. Interviews
were by telephone and semistructured in format, lasting approx-
imately 1 hour, and conducted by two members of the research
team. We sought permission to audio-record at the outset of
each interview.
Data Analysis
Data collected from the stage 1 analysis of agency Web sites is
presented descriptively. Categorical and continuous data were
summarized as frequencies and percentages or as medians and
ranges, respectively. Stage 1 results are aggregated across all
agencies and presented in a detailed tabular form. Given the
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Figure 1. Classification of HTA agencies as non–MD-specific or MD-specific (in terms of process, structure, or methods).
objective of this study, aggregate results are also presented sep-
arately for “MD specific” and “non–MD-specific” agencies.
Stage 2 audio-recorded interviews collected from MD-
specific agencies were transcribed. Answers to open questions
were reviewed to identify major topics that were recurrently
reported by the interviewees. These topics were then mapped
to the three HTA perspectives outlined above, that is, agency
structure, processes, and methods. Individual interviews were
then searched for certain expressions (e.g., “efficient,” “chal-
lenge,” or “suggest”) reflecting either positive or negative opin-
ions/recommendations. Those expressions were then linked to
the major themes and coded using NVivo 10 qualitative data
analysis software. To summarize the frequency of item oc-
currence, the following categorization was assigned: “some”
(10–30 percent of respondents), “many” (31–65 percent), and
“most” (66–100 percent) (19).
RESULTS
Selection of Included HTA Agencies
A total of 135 HTA agencies were identified; after applying our
exclusion criteria, 36 agencies across 20 non-EU countries were
included for analysis (see Supplementary Figure 2).
Stage 1: Web Site Data Collection. Web site data collection was completed
for all thirty-six HTA agencies between June and September
2013; thirty-one (86 percent) data collection sheets were vali-
dated by an agency representative. Twenty-seven of the thirty-
six agencies were considered to be “MD-specific” because they
reported MD-specific information about either their organiza-
tional structure (21; 58 percent), processes (18; 50 percent), or
methods (1; 3 percent) in stage 1 (Figure 1). The most common
model of MD-specific organizational structure was an agency
that retained a broad HTA remit (i.e., assessed the full range of
health technologies including drugs, diagnostic, public health
interventions) but had also developed, within the organization,
a specific staff grouping with collective expertise in medical
device HTA (e.g., Canadian Agency for Drugs and Technolo-
gies in Health (CADTH)). In contrast, the Medicines Advisory
Services Committee (MSAC) in Australia is an example of
agency established with specific remit for the HTA of devices
(along with medical services). Various MD-specific processes
were seen across agencies but could be broadly characterized as
development of specific HTA process pathways for assessment
of devices processes, for example, specific committees for the
appraisal of device technologies.
Structure
The organizational structures of the MD- and non–MD-specific
HTA agencies are compared in Table 1. The two groups of
agencies appeared broadly similar in terms of their funding,
staffing and other element of structure. There were two impor-
tant differences related to handling of MDs. First, whereas the
remit of all HTA agencies included the evaluation of MD tech-
nology, a higher proportion of MD reports were produced by
MD-specific than non–MD-specific agencies (51 percent ver-
sus 10 percent). Second,MD-specific agencies were more likely
to apply a classification system when assessing MDs (e.g., US
Food and Drug Administration (FDA) class III - life-supporting
and life-sustaining products and high-risk devices) than non–
MD-specific agencies (56 percent versus 33 percent).
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Table 1. Summary of Organizational Characteristics of Non-EU Agencies
All agencies MD specific Non-MD specific
(N = 36)a agencies (N = 27)a Agencies (N = 9)a
Characteristics N Median (range) N Median (range) N Median (range)
Annual funding (million USD) 20 2.1 (0.01–24.2) 15 2.3 (0.01—24.20) 5 1.0 (0.4–21.0)
Number of staff 31 25 (3–150) 24 19 (3–150) 7 30 (19- 66)
N (%) N (%) N (%)
Type of organization
National/Central/Federal Government 16 (44) 13 (48) 3 (33)
Local/Provincial/State Government 2 (6) 2 (7) 0 (0)
Academia/university 4 (11) 3 (11) 1 (11)
Compulsory health care insurance (public) 0 (0) 0 (0) 0 (0)
Private medical insurance 1 (3) 1 (4) 0 (0)
Hospital 1 (3) 1 (4) 0 (0)
Professional association 0 (0) 0 (0) 0 (0)
Other not-for-profit 7 (19) 4 (15) 3 (33)
Other 5 (14) 3 (11) 2 (22)
Source of funding
National/Local Governmentb 31 (86) 22 (81) 9 (100)
Private institutionsb 8 (22) 6 (22) 2 (22)
Donor agencies (foundations, research funding bodies, international agencies)b 7 (19) 3 (11) 4 (44)
Otherb 9 (25) 7 (26) 2 (22)
Professional background of staff
Clinical specialist/physician 31 [of 32] (97) 24 [of 25] (96) 7 [of 7] (100)
Economist 26 [of 32] (81) 20 [of 25] (80) 6 [of 7] (86)
Epidemiologist/statistician 26 [of 32] (81) 20 [of 25] (80) 6 [of 7] (86)
Information specialist 19 [of 32] (59) 15 [of 25] (60) 4 [of 7] (57)
Other 27 [of 32] (84) 22 [of 25] (88) 5 [of 7] (71)
Responsible for/contributes to decision-making 15 (42) 12 (44) 3 (33)
Technologies assessed/appraised
Drugs (pharmaceuticals, biologicals, vaccines) 25 (69) 17 (63) 8 (89)
Medical devices 36 (100) 27 (100) 9 (100)
Diagnostics 31 [of 33] (94) 23 [of 25] (92) 8 [of 8] (100)
Medical or surgical procedures 31 [of 33] (94) 23 [of 25] (92) 8 [of 8] (100)
Other technologies 27 [of 35] (77) 20 (74) 6 [of 8] (78)
Organisational or administrative systems 18 (51) 17 (63) 1 (13)
Public health interventions 18 [of 35] (51) 12 (44) 6 [of 8] (75)
Use of medical device classification system 18 (50) 15 (56) 3 (33)
N Median (range) N Median (range) N Median (range)
Average duration of assessment work (months)
Rapid review/response documents 14 1.0 (0.2–6.0) 11 (0.2–6.0) 3 1.2 (1.0–1.5)
Brief technical documents 7 2.2 (1.5–8.0) 5 (1.5–8.0) 2 2.9 (2.2–3.5)
Complete HTA or economic evaluation 18 9.0 (1.0–18.0) 14 10.5 (1.0–18.0) 4 8.2 (4.5–10.5)
Proportion of HTA reports assessing MDs 19 25% (5%–100%) 14 51% (5%–100%) 5 10% (5%–20%)
aAll proportions based on the N = 36 (all agencies), N = 27 (MD specific agencies), N = 9 (Non MD specific agencies) unless otherwise indicated.
bA positive response could be given to more than one item.
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Process
A summary of agencies’ processes for conducting HTA is pre-
sented in Table 2. As with structure, the majority of process
characteristics appeared to be very similar across MD-specific
and non–MD-specific agencies. However, there were some ar-
eas of difference. Compared with non–MD-specific agencies,
MD-specific agencies were more likely to have a structured
process (38 percent versus 80 percent), an internal unit (25
versus 67 percent) responsible for priority setting, to prioritize
based on patient outcomes (33 percent versus 59 percent) and
budget impact (33 percent versus 64 percent) and to externally
commission reports (25 percent versus 44 percent).
Methods
Table 3 summarizes the scientific methods adopted by HTA
agencies. Sixty nine percent of all agencies had a methods guid-
ance document or policy for evidence submission. However,
only one agency, the Department of Science and Technology
in Brazil, reported that they have developed scientific methods
guidelines specifically for the HTA of MDs. No agencies stated
that they were in process of developing MD-specific methods
guidance. Areas of difference between MD-specific and non–
MD-specific agencies were: consideration of organization as-
pects (63 percent versus 33 percent), observational studies (35
percent versus 14 percent), expert opinion (52 percent versus
14 percent), and MD-specific attributes (52 percent versus 33
percent), the use of cost consequence (48 percent versus 14
percent) and cost minimization methods of economic evalua-
tion and specific processes to ensure transferability (47 percent
versus 0 percent).
Stage 2: Semi-structured Interviews. All twenty-seven HTA agencies that
were judged in stage 1 to be MD-specific were invited to par-
ticipate in a follow up interview process (stage 2). Eighteen (67
percent) agencies agreed to be interviewed. In most cases, the
interviews were conducted by telephone with the same agency
individual(s) who verified the Web assessment questionnaire.
In one case, a telephone interview was not possible and instead
responses were obtained by e-mail. After an iterative process
of qualitative data analysis, the following seven broad themes
were identified: (i) capacity; (ii) complex intervention and co-
dependency; (iii) decision making; (iv) evidence; (v) coordina-
tion; (vi) decision problem; (vii) transferability. In a next step,
these themeswere subsumed under the three dimensions ofHTA
used earlier in this report (i.e., structure, process and methods).
A tabulated summary of the results of the semi-structured in-
terviews is available in Supplementary Table 1.
Structure
Decision Making. Some interviewees indicated that their organiza-
tional structure effectively evolves to meet the needs of decision
makers as it relates to HTA of MDs. By adapting the organi-
zational structure according to the objectives outlined in policy
requirements rather than by an HTA “codebook,” agencies con-
tend that they are better positioned to efficiently inform key
funders about the medical, social, economic, and ethical issues
associated with introducing a new technology into the health
care system. One interviewee from an MD-specific agency pur-
ported:
“The structure of the HTA has evolved to meet the funding
programs; it directly reflects that need and not the other way
round (not build on an HTA-centric view). HTA serves the need
of the policy requirement and its organizational structure fits
with what is expected from it.”
They find that this approach reduces the time needed to
translate MD-specific evidence into the health system.
Capacity. Many interviewees cited insufficient resources (e.g.,
budget, skilled economists) as a limitation, creating hurdles
in the agency’s ability to adapt to policy needs for HTA of
MDs. For example, one key informant explained that the lack
of resources has a trickle-down effect on the way in which their
agency is able to examine MD evidence:
“Not enough [MD] experts – there is a very large gap there.
So we only look at evidence in the sense of systematic reviews,
meta-analysis.”
Process
Capacity. Some interviewees indicated that they integrate external
academic partners into the HTA process for MDs when they do
not have staff with the appropriate skills to perform evidence
assessments. In fact, the use of external networks was even cited
as an asset by some interviewees. For example:
“I think some of the real operational issues related to med-
ical technologies are important to understand – How this piece
of equipment works in the hospital, who’s using it, what happens
if it’s in a different pair of hands? I think we don’t necessarily
have a lot of that expertise in house. I’d say one of our strengths
is building those networks.”
Coordination. Some interviewees noted the value of integrating sub-
ject matter experts in the HTA process for MDs. The input of
experts fosters stakeholder buy-in on policy decisions resulting
from evidence appraisals. Furthermore, it supports the contex-
tualization of MD evidence and the introduction of MDs into
the health system.
Another issue identified by many interviewees is that the
introduction of MDs into the healthcare system is diverse and
not standardized:
“For devices, our health care system is extremely fractured.
Devices can come into our system at a regional level, hospital
level, within a particular doctors’ office, at a provincial level,
or even at a national level. So, for devices we have an extremely
fractured system for entry points. Because of that, we have
different kinds of evidence requirement at different kinds of
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Table 2. Summary of HTA Process Across Non-EU Agencies
Non-MD
MD Specific Specific
All Agencies Agencies Agencies
(N = 36) (N = 27) (N = 9)
Characteristics N (%)a N (%)a N (%)a
Process for priority setting 23 [of 33] (70) 22 (80) 3 (38)
The unit responsible for priority setting is:
Internal Unit (e.g., Executive board, scientific committee)b 18 [of 32] (56) 16 [of 24] (67) 2 (25)
External Unit (e.g., government, insurance company)b 20 [of 32] (63) 15 [of 24] (54) 7 (88)
Technologies are selected/prioritised for assessment by:
Perceived impact on patient outcomesb 15 [of 28] (54) 13 [of 22] (59) 2 [of 6] (33)
Budget impact of the technologyb 16 [of 28] (57) 14 [of 22] (64) 2 [of 6] (33)
Prevalence of medical condition 16 [of 28] (57) 13 [of 22] (59) 3 [of 6] (50)
Assessment feasibility (e.g., available data, funding)b 9 [of 28] (32) 8 [of 22] (36) 1 [of 6] (17)
Any new technologyb 1 [of 28] (4) 1 [of 22] (5) 0 [of 6] (0)
Selected new technologyb 12 [of 28] (43) 10 [of 22] (45) 2 [of 6] (33)
Technology identified by external stakeholdersb 19 [of 28] (68) 15 [of 22] (68) 4 [of 6] (67)
Otherb 9 [of 28] (32) 7 [of 22] (32) 2 [of 6] (33)
The assessment work is performed by
Mainly in-house HTA staff 25 [of 34] (74) 19 (72) 7 (78)
Mainly outsourced 7 [of 34] (21) 5 (19) 2 (22)
Other 2 [of 34] (6) 3 (11) 0 (0)
The organisation
Commissions reportsb 13 [of 33] (39) 11 [of 25] (44) 2 [of 8] (25)
Commissioned to perform reportsb 25 [of 33] (76) 18 [of 25] (72) 7 [of 8] (88)
The assessments are based on
Submissions from external stakeholdersb 24 [of 32] (75) 18 [of 25] (72) 6 [of 7] (86)
Internally conducted researchb 14 [of 32] (44) 11 [of 25] (44) 3 [of 7] (43)
Products or services produced by the organisation:
Reports for decision makersb 32 [of 34] (94) 23 [of 25] (92) 9 (100)
Research projects with primary datab 11 [of 34] (35) 9 [of 25] (36) 3 (33)
Academic and training activitiesb 19 [of 34] (56) 12 [of 25] (52) 6 (67)
Clinical practice guidelinesb 13 [of 34] (38) 10 [of 25] (40) 3 (33)
Otherb 7 [of 34] (21) 6 [of 25] (24) 1 (11)
Types of HTA reports produced
Full HTA reportb 24 [of 30] (83) 20 [of 24] (83) 5 [of 6] (83)
Rapid HTA reportb 20 [of 30] (67) 15 [of 24] (63) 5 [of 6] (83)
Otherb 19 [of 30] (63) 14 [of 24] (58) 5 [of 6] (83)
Assessment results are made publically available on
Agency web siteb 26 [of 35] (74) 20 [of 27] (74) 6 [of 8] (75)
INAHTA databaseb 12 [of 35] (34) 10 [of 27] (37) 2 [of 8] (25)
Otherb 14 [of 35] (40) 11 [of 27] (44) 2 [of 8] (25)
Stakeholders (i.e., clinical specialist, patients’ associations, industry) role in the HTA process:
Trigger HTA processb 21 [of 34] (62) 17 [of 26] (65) 4 [of 8] (50)
Involved in the assessment processb 16 [of 34] (47) 11 [of 26] (42) 5 [of 8] (63)
Involved in the appraisal processb 12 [of 34] (35) 10 [of 26] (38) 1 [of 8] (25)
Involved in reimbursement/pricing decisionsb 7 [of 34] (21) 6 [of 26] (23) 1 [of 8] (13)
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Table 2. Continued.
Non-MD
MD Specific Specific
All Agencies Agencies Agencies
(N = 36) (N = 27) (N = 9)
Characteristics N (%)a N (%)a N (%)a
External review of HTA assessments 27 [of 33] (82) 21 [of 21] (81) 6 [of 7] (86)
Have specific measures to ensure transparency of HTA process (e.g. declaration of conflict of interest) 21 [of 23] (91) 18 [of 19] (95) 3 [of 4] (75)
Repeat assessments of given technologies in regular intervals 15 [of 29] (52) 14 [of 23] (61) 1 [of 6] 17
The individual or body responsible for technology funding/coverage/policy decision at end of HTA process
A committee within the same organization 7 [of 33] (21) 6 [of 25] (24) 1 [of 8] (12)
A different organisation 26 [of 33] (78) 19 [of 25] (76) 7 [of 8] (88)
HTA is mandatory for decision making 10 [of 33] (31) 11 [of 25] (44) 0 [of 8] (0)
Decision-making body can deviate from HTA results 30 [of 31] (97) 22 [of 23] (96) 8 [of 8] (100)
aAll proportions based on the N = 36 (all agencies), N = 27 (MD specific agencies), N = 9 (Non MD specific agencies) unless otherwise indicated.
bA positive response could be given to more than one item.
levels. I would go so far to say at some levels there is no rigorous
evidence assessment taking place.”
Although many interviewees acknowledge that the proce-
dure used to review devices, including evidence requirements, is
inextricably linked to the point of entry into the health care sys-
tem, they expressed discontent with the poor levels of evidence
required for pre-market access for MDs.
Many also found fault with the level of harmonization be-
tween the regulatory and reimbursement bodies’ evidence re-
quirements. In consequence, this imbalance leads to unneces-
sarily prolonged review processes.
“The fact of having an evaluation of sanitary registration
for marketing that does not use the same principles as are used
for incorporation in the Public Health System, are considerable
obstacles in HTA for MD.”
Complex Interventions/co-dependency. Another topic was how agencies
manage complex interventions, that by definition include MDs,
and the evidence assessment process for co-dependent technolo-
gies, for example, delivery of drug using a device technology.
Responses were suggestive in nature, including recommenda-
tions on how to improve the management of MDs in complex
environments as well as harmonize the review process by hav-
ing co-dependent technologies simultaneously reviewed by drug
and device assessment committees.
Decision Making. Some agencies noted that the approval channels
integrated into their standard operating procedures mitigate po-
tential challenges associated with translating MD evidence into
policy. For example, one key informant describes current review
processes as sufficient for advising decision makers on whether
to adopt a new technology:
“In health technology assessment term, I think there is not
any raised problemofHTAofMDs. The appliedHTAofMDs has
been discussed and assessed by sub-committee which consist of
qualified medical doctors in their specialty, and has been re-
discussed internally whether to accept, modify or reject the
assessment of sub-committee.”
Methods
Evidence. Most interviewees stated that there is a lack of method-
ological guidance forMDs. Furthermore, they identified several
shortcomings with evidence requirements for MDs.
“The main problem of health technology assessment is sys-
tematic literature review that search, analyze and contemplate
existing studies [ . . . ] The main problems of literature review
are that any newly emerging technologies which have potential
benefit for patients but lack of literature evidence will not be
approved as new technologies.”
The quality of evidence (e.g., lack of randomized trial ev-
idence) was cited several times as the main challenge for per-
forming HTA of MDs.
“The main challenge is that there is not enough good evi-
dence [ . . . ] I think that there is a broad societal question of how
we will ever collect enough data to answer all the questions we
need to answer. I think that that’s really the biggest challenge.”
The quality of evidence was also described as being a lim-
iting factor for the scope of device assessments.
“There are certainly again limitations on what we can do
with the devices given the nature of the evidence base.”
The MD industry was identified by some interviewees as a
“conspirator” to poor evidence generation. As a result, agencies
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Table 3. Summary of HTA Methods of Non-EU Agencies
All Agencies MD Specific Non-MD Specific
(N = 36) Agencies (N = 27) Agencies (N = 9)
Characteristics N (%)a N (%)a N (%)a
Guidance document/policy for methods of evidence submission and/or methods of conduct for assessment 22 [of 32] (69) 17 [of 24] (71) 5 [of 8] (63)
Methods guidance available on website 15 [of 30] (50) 12 [of 22] (55) 3 [of 8] (38)
Comparators used during assessment
Placebob 6 [of 29] (21) 5 [of 24] (21) 1 [of 5] (20)
All relevant health technologiesb 29 [of 29] (100) 24 [of 24] (100) 5 [of 5] (100)
Evolution stage at which technologies are assessed
Emerging/new technologyb 33 [of 34] (97) 25 [of 25](100) 8 (89)
Established or widespread practiceb 25 [of 34] (74) 17 [of 25] (68) 8 (89)
Declining use in practiceb 8 [of 34] (24) 8 [of 25] (32) 0 (0)
Elements of technology evaluated
Health problem and current use of technology 29 [of 36] (81) 22 [of 27] (81) 7 (78)
Description/technical characteristics of technology 29 [of 36] (81) 21 [of 27] (78) 8 (89)
Safety 35 [of 36] (97) 27 [of 27] (100) 8 (89)
Clinical effectiveness 35 [of 36] (97) 26 [of 27] (96) 9 (100)
Costs and economic evaluation 34 [of 36] (94) 26 [of 27] (96) 8 (89)
Ethical aspects 23 [of 36] (64) 18 [of 27] (67) 5 (55)
Organisational aspects 20 [of 36] (56) 17 [of 27] (63) 3 (33)
Legal aspects 10 [of 36] (28) 7 [of 27] (26) 3 (33)
Social aspects 17 [of 36] (47) 11 [of 27] (41) 6 (67)
Assessment methodologies adopted
Systematic review 31 [of 33] (94) 24 [of 25] (96) 7 [of 8] (88)
Meta-analysis 24 [of 33] (73) 19 [of 25] (76) 5 [of 8] (63)
Clinical evaluation 18 [of 33] (55) 15 [of 25] (60) 3 [of 8] (38)
Trials (observational) 9 [of 30] (30) 8 [of 23] (35) 1 [of 7] (14)
Trials (interventional) 9 [of 30] (30) 7 [of 23] (30) 2 [of 7] (29)
Expert opinion 13 [of 30] (30) 12 [of 23] (52) 1 [of 7] (14)
Economic analyses 27 (82) 21 (84) 6 (75)
Clinical trial based economic evaluation 14 (43) 11 [of 23] (48) 2 [of 7] (29)
Decision model based economic evaluation 27 (83) 20 [of 23] (87) 5 [of 7] (71)
Consideration of MDs specific attributes 17 (47) 14 (52) 3 (33)
Type of analyses allowed/recommended in full economic evaluation
Cost-effectiveness 27 [of 28] (96) 20 [of 21] (95) 7 [of 7] (100)
Cost-utility 22 [of 28] (79) 17 [of 21] (81) 5 [of 7] (71)
Cost consequences 11 [of 28] (39) 10 [of 21] (48) 1 [of 7] (14)
Cost minimization 12 [of 28] (43) 10 [of 21] (48) 2 [of 7] (29)
Other 4 [of 28] (14) 4 [of 21] (19) 0 [of 7] (0)
Perspectives considered for economic analyses
Societal 12 [of 29] (41) 10 [of 23] (43) 2 [of 6] (33)
Third party payer 17 [of 29] (59) 13 [of 23] (57) 4 [of 6] (67)
Other 7 [of 29] (24) 6 [of 23] (26) 1 [of 6] (17)
Estimation of uncertainty (e.g. confidence intervals) considered 11 [of 23] (48) 7 [of 17] (41) 4 [of 6] (67)
Public thresholds used to determine cost-effectiveness 4 [of 28] (14) 2 [of 22] (9) 2 [of 6] (3)
National specific data mandatory 8 [of 27] (30) 6 [of 22] (29) 1 [of 6] (33)
Formally uses HTA evaluations conducted by other organisations or countries 18 [of 28] (64) 12 [of 21] (57) 6 [of 7] (86)
Specific processes to ensure transferability 7 [of 17] (41) 7 [of 15] (47) 0 [of 2] (0)
aAll proportions based on the N = 36 (all agencies), N = 27 (MD-specific agencies), N = 9 (non–MD-specific agencies) unless otherwise indicated.
bA positive response could be given to more than one item.
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experienced challenges with obtaining the appropriate evidence
for HTA of MD.
Capacity. Some interviewees identified human resource con-
straints as a great challenge when attempting to apply scientific
methods to critique MD evidence. The range of staff skills tend
to be limited. An interviewee described how they are address-
ing skill deficiencies such as the ability to appropriately evaluate
various types of evidence or data.
“We’ve also recognized the need to put a real focus in terms
of getting our staff comfortable with qualitative research. I’m
not sure we’ll get it to where it needs to be in the next year, but
at least getting people to understand what qualitative research
can bring to an assessment on the non-drug side and especially
with respect to the non-clinical, non-economic of HTA. Within
the team that we have here, we’re working to build awareness
of what it is and why it’s important and then to be able to take
on some projects to get people actually using it and doing it and
then get their comfort level up.”
Transferability. Many interviewees identified the inability to gener-
alize the findings obtained from MD evidence reviews to their
local context as highly problematic.
“The methodology of HTA of MDs can be really difficult.
All we know is generally translated from drugs to devices but
we know that differences exist, for instance the performance
of devices in clinical practice can be very different from that
assessed in controlled setting.”
This weakness was attributed to device-specific challenges,
such as the learning curve. Interviewees believed that interven-
tion evidence, typically generated in environments with highly
skilled staff, may not be representative of the health system
where the technology will be introduced:
“Such another issue, an issue that probably exists here and
elsewhere is that the early use and early evidence on devices
tend to be in individuals with “the best hands problem”- so
specialized academic centers that either develop technologies
themselves or have used it for a number of years. So it’s very
difficult to then generalize what the findings might be in the
community.”
DISCUSSION
Main Findings of the Study
In addition to providing a detailed survey of the practices and
methods of a comprehensive sample of non-EU HTA agen-
cies, this study specifically sought to characterize and compare
current HTA activities for MDs across these agencies. In partic-
ular, we assessed agencies in terms their organizational struc-
ture, processes, and scientific methods. All 36 HTA agencies
identified within our sampling framework undertook the evalu-
ation of MDs. A substantive proportion (27/36; 75 percent) of
HTA agencies reported that they had developed specific ap-
proaches within their organizational structure or procedures
for the assessment or appraisal of MD technologies (“MD-
specific agencies”). For example, organizational developments
included the allocation of specific staff to MDs assessment or
the setup of a completely separate program or unit within the
agency for device evaluation. Procedural developments could
include convening a specific committee to appraise MDs ev-
idence and provide policy advice. There appeared to be few
differences in the organization, process, and methods of be-
tween MD-specific and non–MD-specific agencies. Although
several agencies had a methods guidance document or policy
for evidence submission, only one MD-specific agency (De-
partment of Science and Technology in Brazil) had developed
specific scientificmethodological guidance for the HTA ofMDs
(20).
Our interviews confirmed several commonly cited chal-
lenges in the HTA of MDs (9–11). These included: the rel-
atively poor quality of evidence for MDs, problems in gen-
eralizing the MD evidence obtained in a specific setting to
another, the “learning curve” effect and difficulties in defin-
ing the scope of the appropriate decision problem when con-
ducting HTAs of MDs. This later challenge is particularly em-
phasized by the recent national review of HTA in Australia
in 2011 (21). This review has led to reform the processes by
which the MSAC undertake MDs evaluation, including the in-
troduction of a formal scoping workshop that brings together
key stakeholders (i.e., industry, clinicians, and patients) to have
the opportunity to debate and finalize the scope of the deci-
sion problem (e.g., in terms of the population, comparator(s),
and key outcomes) before the state of the actual assessment of
evidence.
That the vast majority of agencies identified in this survey
has not developed MD-specific methods guidelines indicates
that these agencies applied the same methodological approach
to the assessment of MDs evidence as non-device technolo-
gies, such as drugs. However, we did identify an innovative
approach to evidence generation for MDs. The MaRS Excel-
lence in Clinical Technology Evaluation (EXCITE) program
recently established in Ontario (22), has been developed to in-
tegrate research and development directly into the health care
system to collect the evidence necessary to support “parallel
submission” with both regulators and HTA decision-making
authorities. At the time we completed our survey, the EXCITE
program was recruiting patients for its first randomized con-
trolled trial of a MD (SymplicityTM catheter renal ablation ther-
apy for treatment-resistant hypertension), specifically designed
to facilitate parallel submission to Health Canada, for regula-
tory purposes, and to the Ontario Health Technology Advisory
Committee (23). Other ongoing EXCITE projects include elec-
trical stimulation for upper limb movements in stroke patients,
home sleep apnea events detector, and RNA disruption assay
for early prediction of complete response to chemotherapy in
breast cancer patients (24).
INTL. J. OF TECHNOLOGY ASSESSMENT IN HEALTH CARE 31:3, 2015 162
. https://doi.org/10.1017/S0266462315000185
Downloaded from https://www.cambridge.org/core. University of Glasgow Library, on 21 Feb 2020 at 15:22:06, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms
Health technology assessment of medical devices
Comparison to Previous Literature
Whereas there have been several previous surveys of interna-
tional HTA agency practice, we believe this to be the first inter-
national survey of HTA practice to focus on MDs evaluation.
Three previous studies have included aspects of their review of
HTA practice to the consideration of MDs. In 2012, Stephens
et al. published a survey of thirty HTA organizations represent-
ing sixteen countries including Europe, North and South Amer-
ica, and Australia (5). In accord with our findings, this report
found that themajority of respondents assessedMDs: 94 percent
in Europe and 76 percent in the United States. Similarly, thirty
of the forty-one (75 percent) HTA organizations responding to a
EUNetHTA survey reported to assess MDs (6). In contrast, the
2009 survey by Charles River Associates reported that almost
half of the HTA systems (7/15; 47 percent) did not produce
any HTA reports for MD technologies, unlike reports consid-
ering drugs that were published by all HTA systems (8). The
lower level of MD HTA activity identified in this later survey
can be explained by the sample of HTA agencies which mainly
consisted of drug specific HTA agencies (e.g., Pharmaceutical
Benefits Advisory Committee (PBAC) in Australia, Pharma-
ceutical Management Agency (PHARMAC) in New Zealand,
The Dental and Pharmaceutical Benefits Agency (TLV) in Swe-
den). In addition, other components of HTA activity within
those same countries were ignored (i.e., MSAC and Australian
Safety and Efficacy Register of New Interventional Procedures-
Surgical (ASERNIP) in Australia, New Zealand Health Tech-
nology Assessment (NZHTA) in New Zealand, Swedish Coun-
cil on Technology Assessment in Health Care (SBU) in
Sweden).
Strengths and Limitations
The main strengths of this study include the comprehensive
and systematic approach to the selection of HTA agencies, high
levels of response both to the request for verification of our
agency Web-site surveys and interview invitations, and quality
assurance measures for data collection (development of struc-
tured questionnaire to assess agency Web sites and a second
researcher to verify the all Web-site based assessments and in-
terviews).
However, we acknowledge several potential limitations. As
the scope of this survey was limited by the funder of the project
to consideration of non-EU HTA agencies, our findings may
not be directly generalizable to the EU jurisdiction. A conse-
quence of the comprehensiveness of our survey was the inclu-
sion of a heterogeneous group of HTA agencies (e.g., size, age).
Although we largely took a summative (“average”) approach
to the presentation of results across agencies, where possible,
we did report ranges. The assessment of agency Web sites for
some countries (e.g., Norway) was limited to text and mate-
rial available in English, excluding content in other languages.
However, to minimize the risk of this retrieval bias, key in-
formants reviewed the accuracy of the country-level analysis
and Web-based assessment form. An alternative approach that
may have led to more direct collection of data would have been
to directly request agencies to self-complete a questionnaire.
Although this later approach has been undertaken by several in-
ternational surveys of HTA agencies, it has the major limitation
of a low response rate. For example, the ISPOR and EUNetHTA
surveys that both used questionnaires reported response rates
of only 42 percent and 36 percent, respectively (5;6). Finally,
to compare the approaches of HTA of MDs with drugs, a con-
trast between so-called “MD-specific” agencies versus “non–
MD-specific” HTA agencies (i.e., between agency comparison)
was conducted. It is possible that a within agency analysis (i.e.,
comparison of structure, processes, and methods of the MD and
non-MD technology assessment within the same agency) may
have been more sensitive to detecting differences. However, the
data collection methods were not designed to undertake such
a within agency comparison of HTA approaches as the avail-
able Web-site material does not often differentiate between the
evaluation of differing health technologies.
Implications for Policy
Our findings raise some important implications. First, in con-
trast to the regulatory requirements that appear fairly consistent
across international settings (25), we found that HTA organiza-
tional structures, processes, and scientific methods for MDs can
vary considerably across countries. Second, although it is well
accepted that MDs differ from other health technologies, little
evidence of differentiation in the HTA methods used by agen-
cies for devices compared with drugs was found. This raises
the question of whether these differences are such to require a
fundamentally different methodological approach to the HTA of
MDs compared with drugs or, instead, specific organizational or
procedural adaption to current HTA activities, to consider MD-
specific issues. Scientific methods to deal with usual challenges
posed by MDs evaluation are being developed (26–28) and are
part of the armamentarium of HTA analysts regardless of the
type of technologies evaluated. Third, for other jurisdictions to
develop innovative MD evaluation initiatives, such as Ontario’s
EXCITE programs, several factors need to be in place. For ex-
ample, an infrastructure must exist to support trial development.
The EXCITE program was introduced in a setting where aca-
demic centers with experience in field evaluation and coverage-
with-evidence development activities already existed. Another
important requirement is that a mutual understandingmust exist
between the various stakeholders, and in particular, the differ-
ent incentives between device manufacturers, academics, and
policy makers must be aligned. Finally, appropriate financing is
necessary to support such activities. As many interviewees have
noted, the issue is more about capacity building and training on
advanced methodological tools for HTAMD assessors. The on-
going EXCITE MD trial is funded by a device manufacturer
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although, importantly, the data collection, analysis and report-
ing of the studies is overseen by an independent Trial Steering
Committee (23).
Conclusions
This survey provides a unique overview of organization and
practices of non-EU HTA agencies. It is widely cited that MDs
differ from other health technologies, in particular, they can
change rapidly, clinical outcomes often depend on training and
experience of operator, and pricing is more dynamic than drugs.
The fact that all the non-EU HTA agencies included in this sur-
vey undertake the evaluation of MDs and do so alongside to
other health technologies such as pharmaceuticals, supports the
principles published by Drummond and colleagues for good
HTA practice: “HTA should include all relevant technologies”
(14). However, given the lack of evidence for differentiation in
scientific methods of HTA used by agencies for evaluation of
devices compared with drugs, our study raises the question of
whether the differences between medical technologies are such
to require a fundamentally different methodological approach
to their HTA, and whether organizational or procedural adap-
tation may suffice to accommodate specific challenges posed
by devices’ evaluation. In other words, existing primary and
secondary scientific methods, including the analysis of obser-
vational studies and evaluation approaches for complex inter-
ventions (26–28), may provide a sufficient methodological basis
for the HTA of MDs.
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